| DC7128 |
Lucitanib(E3810)
Featured
|
E-3810 is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. |
|
| DC9595 |
E-4031
Featured
|
E-4031 is a benzenesulfonamide antiarrhythmic agent; blocks the ATP-sensitive potassium channel.
|
|
| DC8533 |
E5555 hydrobromide |
E5555 shows potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC values of 0.064 and 0.031 μM respectively. |
|
| DC23442 |
E-5842 |
E-5842 is a preferential sigma-1 receptor ligand, demonstrates potential atypical antipsychotic effects in vivo. |
|
| DC23416 |
E-5842 hydrochloride |
E-5842 is a preferential sigma-1 receptor ligand, demonstrates potential atypical antipsychotic effects in vivo. |
|
| DC9387 |
E-64
Featured
|
E-64 is a natural, potent, and irreversible inhibitor of cysteine proteases; IC50 values for inhibiting cathepsins K, S, and L, in vitro, are 1.4, 4.1, and 2.5 nM, respectively.
|
|
| DC23728 |
E64FC26 |
E64FC26 is a highly potent pan-style inhibitor of Protein Disulfide Isomerase (PDI) with IC50 of 1.9 uM (PDIA1), also inhibits all other members of the PDI family, including PDIA3, PDIA4, TXNDC5, and PDIA6. |
|
| DC23360 |
E67-2 |
E67-2 is a potent and selective inhibitor of H3K9 Jumonji demethylase KIAA1718 (KDM7A) with IC50 of 3.4 uM. |
|
| DC10563 |
E-7046
Featured
|
E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities. |
|
| DC21898 |
E7090 succinate |
E7090 (E 7090) is a potent, selective, orally available inhibitor of FGFR1, -2, and -3 with IC50 of 0.71, 0.50 and 1.2 nM, weakly inhibits FGFR4 (IC50=120 nM). |
|
| DC22085 |
E7090 |
E7090 (E 7090) is a potent, selective, orally available inhibitor of FGFR1, -2, and -3 with IC50 of 0.71, 0.50 and 1.2 nM, weakly inhibits FGFR4 (IC50=120 nM). |
|
| DC11062 |
E7107 |
E7107 (E-7107) is a derivative of pladienolide that targets the SF3b subunit of the spliceosome, shows significant antitumor activity in vitro and in vivo. |
|
| DC10976 |
E-7386
Featured
|
E-7386 (E7386) is a potent, orally active modulator of CBP/beta-catenin, disrupts the interaction and inhibits canonical Wnt signaling pathway /TCF reporter gene activity in LiCl-stimulated HEK-293 and MDA-MB-231 with IC50 of 55 and 73 nM, respectively. |
|
| DC11037 |
EB-3D |
EB-3D is a novel potent and selective choline kinase ChoKα inhibitor with IC50 of 1.0 uM (purified ChoKα1), strongly impairs cell proliferation in a variety of different cancer cell lines. |
|
| DC20989 |
EBI-1051 |
EBI-1051 is a novel and orally efficacious MEK inhibitor with IC50 of 10.8 nM against MEK1, inhibits viability of colo-205 cells with IC50 of 4.7 nM. |
|
| DC23818 |
EBI-907 |
EBI-907 is a highly potent, selective, orally active B-Raf V600E inhibitor with enzyme IC50 of 7 nM, A375 cell growth IC50 of 13 nM. |
|
| DC20123 |
EC0489 |
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor. Small molecule-drug conjugate (SMDC). |
|
| DC10980 |
EC-359 |
EC-359 (EC359) is a first-in-class, orally available inhibitor of leukemia inhibitory factor (LIF), blocks LIF-LIFR interaction and binds to LIFR with affinity of 81 nM in SPR assay. |
|
| DC20990 |
EC-70124 |
EC-70124 is a multikinase inhibitor with potent activity against several AML related kinases including FLT3, JAK, SYK or Pim kinases (Kd<10 nM). |
|
| DC21514 |
Ecopladib |
Ecopladib (PLA 725) is a potent, selective and orally active inhibitor of cPLA2α with IC50 of 0.15 and 0.11 uM in GLU micelle and rat whole blood assays, respectively. |
|
| DC10400 |
Ecteinascidin 770 |
Ecteinascidin 770 (ET-770) is a 1,2,3,4-tetrahydroisoquinoline alkaloid with potent anti-cancer activities; inhibits U373MG cells with an IC50 of 4.83 nM. |
|
| DC10939 |
Edasalonexent |
Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA). |
|
| DC21002 |
Edelfosine
Featured
|
Edelfosine is a synthetic lysophospholipid analog that selectively inhibits PLC with IC50 of 9.6 uM in fibroblasts and adenocarcinoma cells. |
|
| DC23562 |
Edivoxetine |
Edivoxetine (LY2216684) is a novel potent, selective norepinephrine reuptake inhibitor (NERI) being evaluated as adjunctive treatment for major depressive disorder (MDD).. |
|
| DC23628 |
Edivoxetine hydrochloride |
Edivoxetine (LY2216684) is a novel potent, selective norepinephrine reuptake inhibitor (NERI) being evaluated as adjunctive treatment for major depressive disorder (MDD).. |
|
| DC21515 |
Efipladib |
Efipladib (PLA 902) is a potent, selective and orally active inhibitor of cPLA2α with IC50 of 20 nM for LTB4 inhibition. |
|
| DC10261 |
Eflornithine hydrochloride hydrate |
Eflornithine(Difluoromethylornithine) inhibits polyamine biosynthesis by the selective, irreversible inhibition of ornithine decarboxylase (ODC). A chemoprotective agent that blocks angiogenesis. Its biological half-life is 8 hours. |
|
| DC20992 |
eFT226 |
eFT226 is a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex. |
|
| DC9755 |
eFT508(Tomivosertib)
Featured
|
Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. |
|
| DC22086 |
EG00229 free base |
EG00229 is a specific inhibitor of neuropilin-1 (NRP1)/VEGF-A interaction, inhibits the binding of biotinylated VEGFA to NRP1 with IC50 of 8 uM. |
|
